Fierce Pharma

JUNE 2, 2024

A 50% improvement on the time patients could live without disease progression would typically be considered remarkable for a new drug. AstraZeneca’s Tagrisso just delivered an 84% improvement. | A 50% improvement on the time patients could live without disease progression would typically be considered remarkable for a new drug. AstraZeneca’s Tagrisso just delivered an 84% and earned a standing ovation at ASCO 2024.

Patients 307

Patients 307

MedCity News

JUNE 2, 2024

As majorly disruptive cyberattacks continue to make headlines in the healthcare world, hospitals are prioritizing cybersecurity more than ever before. This piece explores reactions from five different health system executives about the recent attack on Ascension — as well as what they’re doing to prevent a similar fate at their own organization and how they want things to change going forward.

Healthcare 124

Healthcare Healthcare Networking 124

Fierce Pharma

JUNE 2, 2024

On the eve of the American Society of Clinical Oncology’s annual meeting last week, a piece of news set off vigorous discussions. | After Akeso and Summit's ivonescimab beat Keytruda in a head-to-head trial in non-small cell lung cancer, analysts are trying to sort out the financial ramifications while biopharma insiders are eager to see the exact data.

Biopharma 295

Biopharma 295

MedCity News

JUNE 2, 2024

Shedding light on misconceptions about testosterone and women’s health The post How Testosterone is Revolutionizing Menopause Care appeared first on MedCity News.

Physicians 116

Physicians 116

Advertisement

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

Sales Management

pharmaphorum

JUNE 2, 2024

An AI tool has shown impressive results in raising colorectal cancer screening rates in underserved populations, according to data presented at ASCO

122

122

MedCity News

JUNE 2, 2024

Gameto’s $33 million Series B funding round was led by Two Sigma Ventures and RA Capital. The funding will help with the clinical development of its in vitro maturation product called Fertilo. The post Gameto Secures $33M To Support Clinical Development of Fertility Treatment appeared first on MedCity News.

Biopharma 116

Biopharma 116

MedCity News

JUNE 2, 2024

AstraZeneca’s Tagrisso and Imfinzi helped patients live longer in separate pivotal clinical trials evaluating the drugs in two different types of lung cancer. The results will be presented Sunday during the annual meeting of the American Society of Clinical Oncology. The post At ASCO, AstraZeneca Adds Data Supporting Expanded Use of Its Drugs in Lung Cancer appeared first on MedCity News.

Patients 112

Patients Biopharma Pharma 112

PharmaTech

JUNE 2, 2024

Asking why things are done a certain way will help make an accurate assessment of an organization’s EM program, says Susan Schniepp, distinguished fellow at Regulatory Compliance Associates, and Zachary S. Anderson, global market segment lead—Sterility Assurance, Nelson Laboratories.

Leads 52

Leads Marketing 52

MedCity News

JUNE 2, 2024

Now is the time for the entire industry to understand what newborn screening and newborn sequencing programs are, how they benefit the rare disease community, and how to maximize their benefits. The post Newborn Screening + Genome Sequencing: The Formula for Faster Rare Disease Diagnosis? appeared first on MedCity News.

108

108

Pharmaceutical Technology

JUNE 2, 2024

If Enhertu gets approved in the first-line setting metastatic breast cancer setting, 4,200 patients a year could be eligible to receive it.

Patients 52

Patients 52

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Patients

MedCity News

JUNE 2, 2024

GSK’s Blenrep has pivotal clinical trial results showing the multiple myeloma therapy reduced the risk of disease progression or death by nearly 50%. The results were presented Sunday during the annual meeting of the America Society of Clinical Oncology. The post GSK’s Quest to Bring Myeloma Drug Back to the Market Stops for a Data Drop at ASCO appeared first on MedCity News.

Marketing 89

Marketing Biopharma Pharma 89

Pharmacy Times

JUNE 2, 2024

Matthew A. Gubens, MD, MS, FASCO, highlights the importance of identifying genetic targets in metastatic non–small cell lung cancer (NSCLC), emphasizing the latest updates and strategies.

FDA 46

FDA 46

PharmaTech

JUNE 2, 2024

Webinar Date/Time: Thu, Jun 20, 2024 11:00 AM EDT

52

52

Pharmacy Times

JUNE 2, 2024

Understanding patients’ specific experiences and challenges is crucial to helping them improve medication adherence.

Medical 47

Medical Patients 47

Advertisement

Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten

Sales

Pharmacy Times

JUNE 2, 2024

Results from the trial provide evidence bolstering ASCO’s clinical practice guideline supporting the integration of early palliative care into standard oncology practice.

Patients 37

Patients 37

Pharmacy Times

JUNE 2, 2024

Data presented at ASCO 2024 show fam-trastuzumab deruxtecan-nxki (T-DXd) delayed cancer growth in patients with hormone receptor-positive (HR+), HER2-low or -ultralow disease that progressed following endocrine therapy (ET).

Patients 26

Patients 26

Pharmacy Times

JUNE 2, 2024

The phase 3 LAURA trial data presented at ASCO 2024 showed osimertinib (Tagrisso; AstraZeneca) reduced risk of disease progression or death in patients with stage 3 EGFR-mutated (EGFRm) non–small cell lung cancer (NSCLC) by 84%.

Patients 26

Patients 26